Valneva: E34m profit in H1
(CercleFinance.com) - Valneva reports a net profit of E34m for H1 2024, including proceeds from the sale of the priority review warrant, associated with the approval of Ixchiq in February, pretty much a mirror image of a loss of E35m in the same period last year.
The vaccines company reported adjusted EBITDA of E56.2m, compared with a loss of E28.3m in H1 2023, on total sales that are down almost 4% to E70.8m, including product sales of E68.3m.
Valneva confirms its outlook for FY 2024, with total sales estimated at between E170m and E190m, including product sales of E160m to E180m, and research and development (R&D) expenditure of E60bn to E75m.
We plan to continue to take advantage of the recovery in the travel industry to support our commercial sales growth, and at the same time achieve the various R&D milestones we have set ourselves, says CFO Peter Bühler.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The vaccines company reported adjusted EBITDA of E56.2m, compared with a loss of E28.3m in H1 2023, on total sales that are down almost 4% to E70.8m, including product sales of E68.3m.
Valneva confirms its outlook for FY 2024, with total sales estimated at between E170m and E190m, including product sales of E160m to E180m, and research and development (R&D) expenditure of E60bn to E75m.
We plan to continue to take advantage of the recovery in the travel industry to support our commercial sales growth, and at the same time achieve the various R&D milestones we have set ourselves, says CFO Peter Bühler.
Copyright (c) 2024 CercleFinance.com. All rights reserved.